PHOspholamban RElated CArdiomyopathy STudy - Intervention

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularheartmricardiacclass
  Phrases that lowered it: drugm2accordingparticipation in45
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 30 (lowers risk) · Who can join
• Collaborators: 4 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 13.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 86.3% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Keywords listed: 4 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 295 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM NCT01912534 · started 2014 · scored riskier than 90% of active trials completed
• PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors NCT01583114 · started 2011 · scored riskier than 81% of active trials terminated
• Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy NCT04219826 · started 2020 · scored riskier than 64% of active trials completed
• CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) NCT04136171 · started 2020 · scored riskier than 63% of active trials completed
• Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM NCT05186818 · started 2022 · scored riskier than 74% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.